文献速递肝病

HINT:一种用于乙型肝炎病毒相关慢加急性肝衰竭患者的新型预后模型

HINT: a novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure.
PubMed 文献 · Aliment Pharmacol Ther · 2018-08-01

基于635例HBV-ACLF回顾性队列开发并验证新型预后评分HINT,该评分基于肝性脑病、INR、中性粒细胞计数和促甲状腺激素(TSH),在推导队列中30天死亡AUROC为0.889,显著高于Child-Pugh、MELD、CLIF-SOFA、CLIF-C ACLF和COSSH-ACLF评分;验证队列中除与COSSH-ACLF相当外结果一致。横断面和前瞻性纵向队列显示入院TSH在死亡者中显著更低,连续TSH监测可能有助于预测临床病程。

要点

  • HINT评分基于肝性脑病、INR、中性粒细胞计数和TSH四项指标,推导队列30天死亡AUROC为0.889。
  • 推导队列中HINT的AUROC显著高于Child-Pugh、MELD、CLIF-SOFA、CLIF-C ACLF和COSSH-ACLF评分(均P<0.05)。
  • 验证队列中HINT的AUROC与COSSH-ACLF相当(P=0.357),连续TSH监测可能有助于预测ACLF临床病程。

核心结论

  • HINT作为HBV-ACLF预后评分,比Child-Pugh、MELD、CLIF-SOFA和CLIF-C ACLF评分更简单且更优,至少与COSSH-ACLF评分相当。
  • 连续TSH测量可能有助于预测ACLF的临床病程。

研究设计与样本

  • 回顾性队列纳入635例HBV-ACLF患者,用于开发和验证新型预后评分,其中推导队列n=426、验证队列n=209。
  • 横断面队列n=199和前瞻性纵向HBV-ACLF队列n=56用于阐明甲状腺激素状态与30天死亡率的关系。

主要发现

  • 推导队列中HINT评分在非存活者中显著高于存活者(1.17 ± 2.38 vs -1.87 ± 1.26,P < 0.0001)。
  • 推导队列中HINT对30天死亡的AUROC为0.889,显著高于Child-Pugh、MELD、CLIF-SOFA、CLIF-C ACLF和COSSH-ACLF评分(均P < 0.05)。
  • 验证队列中上述结果得到证实,但HINT的AUROC与COSSH-ACLF相当(P = 0.357)。
  • 甲状腺激素中仅入院时TSH水平在非存活者中显著低于存活者(P = 0.01)。
  • 14天纵向观察中,改善组TSH水平显著升高(P < 0.001),恶化组或波动组无变化;存活者TSH逐渐升高(P < 0.001),非存活者无变化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HBV-related acute-on-chronic liver failure (HBV-ACLF) deteriorates rapidly in the short term, which necessitates accurate initial clinical decision making. AIMS: To develop a novel prognostic score for patients with HBV-ACLF and clarify the role of thyroid hormones in HBV-ACLF. METHODS: A retrospective cohort of 635 HBV-ACLF patients was enrolled to develop and validate a novel prognostic score for HBV-ACLF. Additionally, a cross-sectional cohort (n = 199) and a prospective longitudinal HBV-ACLF cohort (n = 56) were recruited to clarify the association between thyroid hormone status and the 30-day mortality of HBV-ACLF. RESULTS: HINT, a novel prognostic score based on hepatic encephalopathy, INR, neutrophil count, and thyroid-stimulating hormone (TSH) using the deriving cohort (n = 426), was significantly higher in non-survivors than survivors (1.17 ± 2.38 vs -1.87 ± 1.26, P < 0.0001). The AUROC of HINT for 30-day mortality was 0.889, which was significantly higher than that of the Child-Pugh, MELD, CLIF-SOFA, CLIF-C ACLF, and COSSH-ACLF scores (all P < 0.05). These results were confirmed in the validation cohort (n = 209), except that the AUROC of HINT was comparable to that of COSSH-ACLF (P = 0.357). Among thyroid hormones, only the TSH level on admission was significantly lower in non-survivors than in survivors (P = 0.01). During the 14-day longitudinal observation, TSH levels increased significantly in the improvement group (P < 0.001) but did not change in the deterioration or fluctuation groups, and gradually increased in survivors (P < 0.001) but not in non-survivors. CONCLUSIONS: HINT, as a prognostic score for HBV-ACLF, is simpler than and superior to the Child-Pugh, MELD, CLIF-SOFA, and CLIF-C ACLF scores and at least comparable with the COSSH-ACLF score. Sequential TSH measurements may facilitate prediction of the clinical course of ACLF.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wu D, Sun Z, Liu X, et al. HINT: a novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure. Aliment Pharmacol Ther. 2018. PMID: 30069888. doi:10.1111/apt.14927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。